Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05452317 · ClinicalTrials.gov registry record
Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection
A clinical trial, sponsored by CSL Behring.
- Completed
- Registry status
- 52
- Enrollment target
NCT05452317 is a clinical trial that has completed, run by CSL Behring. The registered enrollment target is 52 participants.
The verdict
NCT05452317 has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
Study Summary
This study investigates the burden of disease among kidney transplant recipients that have developed Chronic Active Antibody Mediated Rejection (caAMR) compared with kidney transplant recipients that have not developed caAMR
Interventions
- OTHER Chronic active AMR group
- OTHER Non-Chronic active AMR group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2022-07-14 |
| Est. Completion | 2023-04-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05452317
The ClinicalTrials.gov registry entry for NCT05452317 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Chronic active AMR group is the first listed.
NCT05452317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05452317 about?
NCT05452317 is a clinical study titled "Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection". This study investigates the burden of disease among kidney transplant recipients that have developed Chronic Active Antibody Mediated Rejection (caAMR) compared with kidney transplant recipients that have not developed caAMR
What is the current status of trial NCT05452317?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2022-07-14. Estimated completion is 2023-04-04.
What interventions are being tested in trial NCT05452317?
The interventions under investigation include: Chronic active AMR group (OTHER), Non-Chronic active AMR group (OTHER).
Who is sponsoring clinical trial NCT05452317?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.